Novan, Inc. (NOVN) Stock

About Novan, Inc.

Novan, Inc. operates as a pre-commercial pharmaceutical entity specializing in nitric oxide-derived therapies for dermatological and anti-infective conditions. The company boasts a robust clinical-stage pipeline featuring several topical drug candidates. For skin-related ailments, these include SB204, a monotherapy aimed at acne vulgaris; SB206, an antiviral gel targeting viral skin infections; SB208, a broad-spectrum antifungal gel designed to combat various fungal skin and nail infections like athlete's foot; and SB414, a cream-based gel formulated for inflammatory skin diseases. Additionally, Novan is advancing SB207 to treat external genital warts, WH602 (an intravaginal gel) and WH504 (a non-gel formulation) both addressing high-risk human papillomavirus (HPV), and SB019, a candidate for SARS-CoV-2. The firm has cultivated strategic partnerships, holding a licensing agreement with Sato Pharmaceutical Co., Ltd., and engaging in a strategic alliance with Orion Corporation. Founded in 2006, Novan, Inc. maintains its headquarters in Durham, North Carolina.

Novan, Inc. is headquartered in US.

Novan, Inc. (NOVN) stock trades at $0.09 with a market capitalization of $2.64M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.11, reflecting a net loss over the last twelve months, price-to-book of 0.45, price-to-sales of 0.11. Over the past 52 weeks the stock has ranged between $0.08 and $3.33, and currently trades 97.3% below its 52-week high.

On profitability, Novan, Inc. generates a return on equity (ROE) of -170.66% (negative, reflecting a net loss), return on capital employed of -80.56%, an operating margin of -149.90%, a net profit margin of -82.85%.

Official website: www.novan.com